Literature DB >> 2557614

Epstein-Barr virus/complement fragment C3d receptor (CR2) reacts with p53, a cellular antioncogene-encoded membrane phosphoprotein: detection by polyclonal anti-idiotypic anti-CR2 antibodies.

M Barel1, A Fiandino, F Lyamani, R Frade.   

Abstract

Epstein-Barr virus and the C3d fragment of the third component of complement are specific extracellular ligands for complement receptor type 2 (CR2). However, intracellular proteins that react specifically with CR2 and are involved in post-membrane signals remain unknown. We recently prepared polyclonal anti-idiotypic anti-CR2 antibodies (Ab2) by using the highly purified CR2 molecule as original immunogen. We showed that Ab2 contained anti-idiotypic specificities that mimicked extracellular domains of CR2 and detected two distinct binding sites on CR2 for its specific extracellular ligands, Epstein-Barr virus and C3d. We postulated that Ab2 might also contain specificities that could mimic intracellular domains of CR2. Here we report that Ab2, which did not react with Raji B-lymphoma cell surface components, detected specifically, among all components solubilized from Raji cell membranes, a single intracellular membrane protein of apparent molecular mass of 53 kDa. This protein was identified as the p53 cellular antioncogene-encoded membrane phosphoprotein by analyzing its antigenic properties with Pab1801, a monoclonal anti-p53 antibody, and by comparing its biochemical properties with those of p53. Additionally, solubilized and purified CR2 bound to solubilized p53 immobilized on Pab1801-Sepharose. p53, like CR2, was localized only in purified plasma membranes and nuclei of Raji cells. These data suggest strongly that p53, a cellular antioncogene-encoded phosphoprotein, reacted specifically with CR2 in Raji membranes. This interaction may represent one of the important steps through which CR2 could be involved in human B-lymphocyte proliferation and transformation.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2557614      PMCID: PMC298642          DOI: 10.1073/pnas.86.24.10054

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  42 in total

1.  Mapping of the C3d receptor (CR2)-binding site and a neoantigenic site in the C3d domain of the third component of complement.

Authors:  J D Lambris; V S Ganu; S Hirani; H J Müller-Eberhard
Journal:  Proc Natl Acad Sci U S A       Date:  1985-06       Impact factor: 11.205

2.  Isolation of human-p53-specific monoclonal antibodies and their use in the studies of human p53 expression.

Authors:  L Banks; G Matlashewski; L Crawford
Journal:  Eur J Biochem       Date:  1986-09-15

3.  Binding of monoclonal antibody to the Epstein Barr virus (EBV)/CR2 receptor induces activation and differentiation of human B lymphocytes.

Authors:  G R Nemerow; M E McNaughton; N R Cooper
Journal:  J Immunol       Date:  1985-11       Impact factor: 5.422

4.  gp 140, the C3d/EBV receptor (CR2), is phosphorylated upon in vitro activation of human peripheral B lymphocytes.

Authors:  M Barel; A Vazquez; C Charriaut; M T Aufredou; P Galanaud; R Frade
Journal:  FEBS Lett       Date:  1986-03-03       Impact factor: 4.124

5.  Structure and functions of gp 140, the C3d/EBV receptor (CR2) of human B lymphocytes.

Authors:  R Frade
Journal:  Mol Immunol       Date:  1986-11       Impact factor: 4.407

6.  Growth control of activated, synchronized murine B cells by the C3d fragment of human complement.

Authors:  F Melchers; A Erdei; T Schulz; M P Dierich
Journal:  Nature       Date:  1985 Sep 19-25       Impact factor: 49.962

7.  B lymphocyte receptors and polyphosphoinositide degradation.

Authors:  M K Bijsterbosch; C J Meade; G A Turner; G G Klaus
Journal:  Cell       Date:  1985-07       Impact factor: 41.582

8.  Specific interaction between the p53 cellular tumour antigen and major heat shock proteins.

Authors:  O Pinhasi-Kimhi; D Michalovitz; A Ben-Zeev; M Oren
Journal:  Nature       Date:  1986 Mar 13-19       Impact factor: 49.962

9.  gp140, a C3b-binding membrane component of lymphocytes, is the B cell C3dg/C3d receptor (CR2) and is distinct from the neutrophil C3dg receptor (CR4).

Authors:  R Frade; B L Myones; M Barel; L Krikorian; C Charriaut; G D Ross
Journal:  Eur J Immunol       Date:  1985-12       Impact factor: 5.532

10.  Tissue-specific phosphorylation of complement receptors CR1 and CR2.

Authors:  P S Changelian; D T Fearon
Journal:  J Exp Med       Date:  1986-01-01       Impact factor: 14.307

View more
  4 in total

Review 1.  Epstein-Barr virus tissue tropism: a major determinant of immunopathogenesis.

Authors:  L Hutt-Fletcher
Journal:  Springer Semin Immunopathol       Date:  1991

2.  Identification on melanoma cells of p39, a cysteine proteinase that cleaves C3, the third component of complement: amino-acid-sequence identities with procathepsin L.

Authors:  D Jean; J Hermann; F Rodrigues-Lima; M Barel; M Balbo; R Frade
Journal:  Biochem J       Date:  1995-12-15       Impact factor: 3.857

3.  Cloning and characterization of anti-cathepsin L single chain variable fragment whose expression inhibits procathepsin L secretion in human melanoma cells.

Authors:  Nathalie Guillaume-Rousselet; Didier Jean; Raymond Frade
Journal:  Biochem J       Date:  2002-10-01       Impact factor: 3.857

4.  A CD21 low phenotype, with no evidence of autoantibodies to complement proteins, is consistent with a poor prognosis in CLL.

Authors:  Eva-Maria Nichols; Rachel Jones; Rachael Watson; Chris J Pepper; Chris Fegan; Kevin J Marchbank
Journal:  Oncotarget       Date:  2015-10-20
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.